Agios Pharmaceuticals Inc. reported $12.9 million in third quarter 2025 PYRUKYND net revenues. Selling, General and Administrative expenses were $41.3 million for the third quarter of 2025, an increase of $2.7 million compared to the same period in 2024, primarily attributed to investments in preparation for a potential U.S. commercial launch of PYRUKYND in thalassemia. The company held $1.3 billion in cash, cash equivalents, and marketable securities as of September 30, 2025, compared to $1.5 billion at December 31, 2024. Agios stated that its current financial position, along with anticipated product revenue and interest income, is expected to support preparations for potential PYRUKYND commercial launches in thalassemia and sickle cell disease, as well as advancement of clinical programs and pipeline expansion. The PDUFA goal date for PYRUKYND's supplemental new drug application in thalassemia is set for December 7, 2025, with a European Commission decision expected by early 2026 following a positive CHMP opinion. Topline results from the RISE UP Phase 3 trial in sickle cell disease are anticipated by year-end, and a Phase 2b tebapivat trial in lower-risk MDS is fully enrolled, with topline results expected in early 2026.